Abstract
Background-Aim
After a patient successfully receives a renal transplant, an increase in total serum cholesterol and triglycerides, a decrease in high density cholesterol, and normal level in low density cholesterol may be noted. Coronary artery disease is one of the main causes of morbidity and mortality in renal recipients. This study was performed in order to determine the lipid profile of patients with chronic kidney disease that received a renal transplant, and correlate the effect of the lipid profile with atherogenesis.
Patients-Methods
The study included 30 patients, of whom 21 were male and 9 female, with a mean age of 48.43 years. The lipid status of all patients was measured one month prior to transplantation and at distinct time intervals (1, 3, 6, 12 months) after transplantation. Echocardiographic (triplex) evaluation was performed in all renal recipients before transplantation and 12 months post surgery. Twenty-nine patients received a renal graft from cadaveric patients while one received a renal graft from a living relative donor. It was the first transplantation for all patients after being on the transplant waiting list for a mean 4.2 years.
Results
Measurements of the lipid profile of these patients revealed statistically significant changes after renal transplantation. Moderate atheromatous lesions were found in 50% of patients before transplantation. One year after transplantation, 18% of patients revealed no atheromatous lesions, 54% had mild atheromatous lesions and 28% had severe atheromatous lesions. Total serum cholesterol levels had statistically significant changes (P<0.001), and the grade of stenosis of carotids was also affected (p=0.0013).
Conclusion
Our results suggest that changes in the lipid status in renal transplant patients are strongly correlated with atherogenesis in carotids and, in consequence, an increased cardiovascular risk for these patients. Long-term follow-up of renal recipients can be of significant use in monitoring cardiovascular disease.
Similar content being viewed by others
References
Health and Consumer Affairs Council Meeting on Employment and Social Policy. Luxemburg-1 and 2 June 2006.
Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart Disease and Stroke Statistics- Update 2010. A report from the American Heart Association. Circulation 2010; 121:e46–e215
British Heart Foundation and Health Economics Research Center, 2008. European cardiovascular disease statistics
Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 256:147–52.
Arend SM, Mallat MJ, Wastendorp RJ, et al. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant 1997; 12:1672–9
Raine AEG. Hypertension and ischaemic heart disease in renal transplant recipients. Nephol Dial Transplant 1995;[suppl 1]; 95–100
Foley RN, Parfrey PS, Sarmak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112–9
Shirali AC, Bia MJ. Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol 2008; 3:491–504
Lindholm A, Albrechtsen D, Frodin L, et al. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60:451–7
Wanner C, Quaschning T. and Weingarnter K. Impact of dyslipidemia in renal transplant recipients Current Opinion in Yrology 2000, 10:77–80
Law M, Wald NU, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease? BMJ 1994; 308:367–72
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prosoectiv analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267–78
Mackay J, Mensah G. Atlas of Heart Disease and Stroke. World Health Organization. Geneva, 2004
Pearson TA, Blair SN, Daniels SR, Eckel RH, et al AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases Circulation 2002; 106:388–91
Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002; 106:2137–42
Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725–30
Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplant candidates: Clinical practice guidelines. Am J Transplant 2001; 2:S5–S95
Saland JM, Ginsberg HN. Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol 2007; 22:1095–112
Abdulmassih Z, Chevalier A, Bader C, Druèeke TB, Kreis H, Lacour B. Role of lipid disturbances in the atherosclerosis of renal transplant patients. Clin Transplant 1992; 6:106–13
Saland JM, Ginsberg HN. Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol 2007; 22:1095–112
Ramezani M, Einollahi B, Ahmadzad-Asl M, Nafar M, Pourfarziani V, Samadpour A, et al. Hyperlipidemia After Renal Transplantation and Its Relation to Graft and Patient Survival. Transplantation Proceedings 2007; 39:1044–7
Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998; 32:S142–56
Pilmore H. Cardiac Assessment for Renal Transplantation. American Journal of Transplantation 2006; 6:659–65
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pistolas, D., Mpalaska, A., Koukoulaki, M. et al. Effect of lipid disorders on arteriosclerosis in renal transplant recipients. Hellenic J Surg 86, 197–202 (2014). https://doi.org/10.1007/s13126-014-0129-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13126-014-0129-6